Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended		36 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015
Patent costs	$ 565,594	$ 342,625
Percentage of concentration of risk related to general and administrative or research and development costs	10.00%
Deferred setup and organization costs, amortization period	180 months
Unrecognized tax benefits	$ 0	0	$ 0
Theradex Systems, Inc [Member]
Clinical costs charged to operations			1,660,725
Theradex Systems, Inc [Member]
Clinical costs charged to operations	$ 958,896	$ 423,108
Percentage of clinical research and development costs	46.00%	38.00%
Theradex Systems, Inc [Member] | Phase 1 Clinical [Member]
Total estimated clinical costs to be charged to operations	$ 2,200,000
Percentage of clinical trial service	60.00%
Percentage of clinical center laboratory cost	40.00%
Theradex Systems, Inc [Member]
Advances on research and development contract services, to Theradex	$ 185,392		185,392
Theradex Systems, Inc [Member] | Mid-2016 [Member] | Phase 1 Clinical [Member]
Advances on research and development contract services, to Theradex	$ 181,510		$ 181,510